Left Ventricular Hypertrophy in CKD Patients
ConditionLeft Ventricular Hypertrophy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSohag University
About this trial
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
The main question it aims to answer is:
Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?
Eligibility criteria
Qualifiers
Adults (≥18 years) diagnosed with CKD stages 3-5.
Stable clinical condition for ≥3 months.
Anemia (Hb <10 g/dL) for cohort phase.
Willingness to participate and provide informed consent.
Disqualifiers
Valvular or ischemic heart disease.
Uncontrolled hypertension (BP >180/110 mmHg).
Acute coronary syndrome or decompensated heart failure in the past 3 months.
Malignancy or active infection
Trial design
Treatments tested in this trial
- transthoracic echocardiography
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov